SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

8 Oct 2013 07:00

RNS Number : 9350P
Victrex PLC
08 October 2013
 



 

 

8 October 2013

Victrex plc - Year End Trading Statement

Victrex plc ('Victrex'), an innovative world leader in high performance polymers, today releases its year end trading statement, ahead of its 2013 preliminary results which will be announced on Tuesday 10 December 2013.

Full year sales volume was slightly ahead of last year at 2,920 tonnes (FY 2012: 2,904 tonnes) following a robust second half performance, with sales volume approximately 10% ahead of the first half year. Group sales volume of 1,528 tonnes for the second half was in line with the strong prior year performance (H2 2012: 1,527 tonnes), with good progress across our industrial and transport markets, offset by lower sales in the electronics market following the non-recurrence of last year's strong product launch related sales into consumer electronics.

In our Invibio Biomaterial Solutions business, full year revenue was slightly ahead of the prior year at £50.8m (FY 2012: £50.5m). This reflects steady improvement in sales to the Spine market during the second half year, with revenue 10% ahead of the first half, as inventory levels in the industry appear to have stabilised. Second half revenue in Invibio was also ahead of the prior year at £26.6m (H2 2012: £25.0m). Outside of the Spine market, we continue to see steady progress in our emerging market opportunities.

Outlook

Looking ahead to our new financial year, whilst we remain mindful of the wider economic environment, our order book for October is reassuring. Victrex remains confident in the diverse and multiple growth opportunities that are being developed across the business. Our investment in additional capacity, which is a key enabler to support and deliver our future growth programmes, remains on plan and on budget, with construction progressing well.

Victrex will host an Investor Day, 'Spotlight on Growth', in London this Thursday, 10 October 2013, with its Executive Management Team, including presentations by Tim Cooper, Managing Director of VPS, and Martin Court, Managing Director of Invibio, covering the scale of Victrex's Group wide growth programmes. No new trading or financial information will be disclosed during the Investor Day. 

 

Enquiries:

Victrex plc:

Andrew Hanson, Head of Investor Relations 01253 898121

Steve Barrow, Group Finance Director 01253 897700

 

MHP Communications:

Nick Denton/Barnaby Fry/James White 0203 128 8100

 

Investor and analyst conference call:

A conference call for Investors and Analysts will be held today, Tuesday 8 October, 09.00am. For further details please contact Ben Griffiths at MHP Communications on 0203 128 8100.

 

About Victrex:

Victrex is an innovative world leader in high performance polymers. Every day, millions of people rely on products or applications which contain our materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 30 years' experience, we are investing in technology leadership to deliver new solutions to our customers and our markets. Find out more at www.victrexplc.com

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGWAUUPWGQM
Date   Source Headline
25th Jul 20137:00 amRNSInterim Management Statement
17th Jul 20131:46 pmRNSDirector/PDMR Shareholding
2nd Jul 201310:54 amRNSHolding(s) in Company
2nd Jul 20137:39 amRNSDirector Declaration
28th Jun 20138:00 amRNSTotal Voting Rights
26th Jun 20139:35 amRNSHolding(s) in Company
25th Jun 201310:43 amRNSHolding(s) in Company
24th Jun 20132:33 pmRNSHolding(s) in Company
21st Jun 20139:13 amRNSHolding(s) in Company
18th Jun 20134:41 pmRNSDirector/PDMR Shareholding
7th Jun 201312:26 pmRNSHolding(s) in Company
5th Jun 20132:02 pmRNSDirector/PDMR Shareholding
3rd Jun 20131:50 pmRNSBlocklisting Interim Review
31st May 20131:49 pmRNSTotal Voting Rights
28th May 20139:02 amRNSHolding(s) in Company
28th May 20137:00 amRNSHalf Yearly Report
20th May 20133:34 pmRNSHolding(s) in Company
17th May 20131:39 pmRNSDirector/PDMR Shareholding
16th May 201310:35 amRNSHolding(s) in Company
14th May 20139:58 amRNSHolding(s) in Company
30th Apr 20133:53 pmRNSTotal Voting Rights
24th Apr 20134:24 pmRNSHolding(s) in Company
22nd Apr 20134:14 pmRNSHolding(s) in Company
22nd Apr 20134:02 pmRNSHolding(s) in Company
17th Apr 20131:54 pmRNSDirector/PDMR Shareholding
16th Apr 20134:34 pmRNSHolding(s) in Company
9th Apr 20137:00 amRNSTrading Statement
3rd Apr 20133:01 pmRNSHolding(s) in Company
28th Mar 20133:00 pmRNSTotal Voting Rights
22nd Mar 20139:51 amRNSHolding(s) in Company
21st Mar 201310:25 amRNSHolding(s) in Company
20th Mar 201312:28 pmRNSDirector/PDMR Shareholding
13th Mar 201312:20 pmRNSHolding(s) in Company
28th Feb 20133:19 pmRNSTotal Voting Rights
28th Feb 20132:49 pmRNSDirector/PDMR Shareholding
27th Feb 201311:05 amRNSHolding(s) in Company
26th Feb 20139:32 amRNSHolding(s) in Company
20th Feb 201311:38 amRNSDirector/PDMR Shareholding
5th Feb 20134:24 pmRNSResult of AGM
5th Feb 20137:00 amRNSAGM and Interim Management Statement
4th Feb 201311:42 amRNSHolding(s) in Company
31st Jan 201312:47 pmRNSTotal Voting Rights
29th Jan 201312:46 pmRNSHolding(s) in Company
23rd Jan 201312:23 pmRNSHolding(s) in Company
17th Jan 20134:13 pmRNSDirector/PDMR Shareholding
8th Jan 201310:24 amRNSHolding(s) in Company
7th Jan 20132:40 pmRNSAnnual Information Update
7th Jan 20132:02 pmRNSAnnual Financial Report
7th Jan 201312:37 pmRNSHolding(s) in Company
28th Dec 201212:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.